Kopenmaar! schreef op 21 juni 2011 20:40:
Biolex gaat pas in 2012 met Fase 3 beginnen:
Hoe is de cashpositie van Octoplus, hoe groot is de kans op een aandelenuitgifte?
Clinical-stage biopharmaceutical company Biolex Biolex Follow this company Therapeutics has closed on an additional $5.9 million, a continuation of its Series D round from 2008.
That increases the Pittsboro-based company’s total venture haul to about $190 million to date.
Biolex uses a technology that genetically transforms the aquatic plant Lemna to produce biologic product candidates. The company’s lead product candidate, Locteron, is a treatment for hepatitis C.
The company states that worldwide sales of interferon products for the treatment of hepatitis C will approach $6 billion by 2016. Biolex also has a product candidate for treatment of blood clots.
Dale Sander, chief financial officer of Biolex, says the funds will be used to prepare Locteron for Phase 3 clinical trials that will begin in 2012. The company is hoping to receive approval from the U.S. Food and Drug Administration by 2016. The company is headed by Jan Turek.
Most recently in March, Biolex announced positive results from a Phase 2b trial of Locteron. Patients treated with Locteron experienced lower rates of depression than patients treated with the control. Biolex is headed by Jan Turek.
“Hepatitis C is an area of great interest, both to the pharmaceutical industry and the investment community,” Sander said Friday.
Claris Ventures of Boston, OrbiMed Advisors of New York, and Durham-based Intersouth Partners are among the company’s investors.